Cathie Wood Rotates Out of Iridium and Into This Biotech Stock — Here’s Why

TLDR ARK Invest sold 176,093 Iridium Communications shares worth $3.32 million after a 6.3% stock price increase on December 10 Wood purchased 11,342 Nurix Therapeutics shares valued at $221,736 following positive blood cancer trial results ARK dumped 35,379 Adaptive Biotechnologies shares worth $525,731 and 4,166 Teradyne shares worth $833,075 Wood reduced Ibotta holdings by 11,700 [...]

The post Cathie Wood Rotates Out of Iridium and Into This Biotech Stock — Here’s Why appeared first on Blockonomi.